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Abstract. Parkinson’s disease (PD) is a very com-
mon neurodegenerative disorder in the elderly for which
there is no current cure. The neuropathological hall-
mark is the loss of dopaminergic cells in the sub-
stantia nigra pars compacta. Current treatments use
L-DOPA and dopamine agonists to replace the lack
of dopamine, however such treatments have signific-
ant limitations and side effects, thus, the need for
more effective therapeutics is critical. Cannabinoids
(CBs), which include ∆9-tetrahydrocannabinol, canna-
bidiol and ∆9-tetrahydrocannabivarin, target the en-
docannabinoid (ECB) system, which is highly involved
in dopaminergic functions. The endocannabinoid sys-
tem undergoes extensive changes in PD such as up-
regulation of the ECB anandamide, in addition to vari-
ations in the concentration of CB receptors. These
changes can be modified and corrected using CB1 and
CB2 receptor ligands and by modulating the levels of
the ECB catabolic enzyme fatty acid amide hydrolase
(FAAH), in order to increase endogenous anandamide
(AEA) levels. Therefore, CBs may represent a valid
therapeutic alternative to treat PD. CB drugs may
not only treat the symptoms of the disease, but may
also help slow down disease progression. Nevertheless,
with regards to motor symptoms of PD such as rigid-
ity, bradykinesia, postural instability, resting tremors
and levodopa-induced dyskinesia, evidence of the thera-
peutic effect of CBs is somewhat inconsistent. Although
only evidence in the preclinical phase, more promising
results have been seen in general regarding the neuro-
protective effect of CBs, as well as in relation to sleep,
depression and pain.
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1 Introduction
Cannabis is derived from a plant named Cannabis sativa
and has been used as a therapeutic agent since an-
cient times; it was clinically recognized as a medi-
cinal compound in the mid-19th century (Borgelt, Fran-
son, Nussbaum & Wang, 2013), following research done
by Sir William B. O’Shaugnessey (Gowran, Noonan &
Campbell, 2010). Medical cannabis has been widely
used in medicine to treat an extensive range of clinical
problems such as inflammation, oxidative stress, spas-
ticity and rheumatism, as well as pain (Gowran et al.,
2010; Babayeva, Assefa, Basu, Chumki & Loewy, 2016;
Fitzcharles & Eisenberg, 2018) and Parkinson’s disease
(PD).
Affecting 1% of the population, PD is the second
most common neurodegenerative disorder, preceded by
Alzheimer’s disease (Xu, Kochanek, Murphy & Tejada-
Vera, 2010). It is estimated that by the year 2030 there
will be approximately nine million cases of PD across the
fifteen highest populated countries in the world (Dorsey
et al., 2006). Today Parkinsonian patients are only
treated with substitutive therapy to compensate the lack
of dopamine in their brain. Therefore, such treatment is
purely symptomatic and does not affect the progression
of the disease, thus there is currently no cure for PD
(Babayeva et al., 2016). Moreover, adverse effects ap-
pear several years after initiation of treatment (as shown
by the graph in Fig. 1) and can include motor fluc-
tuations and dyskinesia (L-DOPA induced dyskinesia:
LID) (Marsden & Parkes, 1977). This review aims to
highlight the effects of such CBs on patients suffering
from PD.
*Correspondence to: Francesca Borg (francesca.m.borg.16@um.edu.mt)
c© 2019 Xjenza Online
66 The Use of Cannabinoids in Parkinson’s Disease
1.1 The Phyto-, Exo- and the
Endocannabinoids
The products extracted from the cannabis plant con-
sist of a large number of phytocannabinoids (phyto-
CBs), a term used to differentiate cannabinoids de-
rived from the plant, from those found in the body
(i.e., endocannabinoids, ECBs) or those chemically
synthesized (i.e., exocannabinoids, exo-CBs). Of
about 85 phyto-CBs contained in the plant there are
two significant ones, namely cannabidiol (CBD) and
delta-9-Tetrahydrocannabinol (∆9-THC) (Russo, 2011;
Babayeva et al., 2016). Synthetic cannabinoids were
made for cannabinoid research (exo-CBs). Exo-CBs en-
compass a variety of distinct chemical classes: the clas-
sical cannabinoids structurally related to THC, the non-
classical cannabinoids (cannabimimetics) including the
aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, and
arylsulfonamides, as well as eicosanoids related to en-
docannabinoids (Lambert & Fowler, 2005). Synthetic
cannabinoids were needed partly due to legal restrictions
on natural cannabinoids, which make them difficult to
obtain for research. At the time of the discovery of the
cannabinoid CB1R, there were just two main chemical
classes of psychotropic cannabinoids: the ‘classical can-
nabinoids’ that consist of tricyclic dibenzopyrans, such
as ∆9-THC and its far more potent synthetic analogue
(−)-11-hydroxy-∆8-THC-dimethylheptyl (HU-210), as
well as ‘nonclassical’ cannabinoids of which the bicyclic
CP55940 is an important member. Subsequently, other
chemical classes of psychotropic cannabinoids made
their appearance, including the aminoalkylindole R-(+)-
WIN55212, endogenous eicosanoids such as anandamide
and 2-arachidonoyl glycerol (see below), in addition to
the more recently discovered, Bayer compound, BAY
38-7271. Some early synthetic cannabinoids were also
used clinically. Nabilone, a first-generation synthetic
THC analog, has been used as an antiemetic to com-
bat vomiting and nausea since 1981. Synthetic THC
(Marinol, dronabinol) has been used as an antiemetic
since 1985 and an appetite stimulant since 1991 (Per-
twee, 2006). The CB1R inverse agonist SR141716 (also
known as rimonabant), was discovered and developed
by Sanofi-Aventis and temporally approved as an anor-
ectic anti-obesity drug, but was later withdrawn in 2008
due to serious psychiatric side effects including suicide
(Sam, Salem & Ghatei, 2011).
In the early 2000s, synthetic cannabinoids began to be
used for recreational drug use in an attempt to achieve
similar effects to that of cannabis. The likelihood of
severe abuse and addiction produced by SCs are of con-
cern for the scientific community who are also interested
in the potential therapeutic value of cannabinoids (Le
Boisselier, Alexandre, Lelong-Boulouard & Debruyne,
2017).
The ECBs consists of several components: lipid-based
molecules called ECBs, CB receptors, transport pro-
teins, as well as enzymes responsible for the synthesis
and degradation of the ECBs (Rodr´ıguez de Fonseca et
al., 2005). Synthesis enzymes include N- arachidonoyl-
phosphatidylethanolamine (NAPE)-specific phospholi-
pase D and diacylglycerol lipase-a (DAGLa), while those
that catabolize the ECBs include fatty acid amide hy-
drolase (FAAH) and monoacylglycerol lipase (MAGL)
(Stampanoni Bassi, Sancesario, Morace, Centonze &
Iezzi, 2017). The body has several ECBs, the most signi-
ficant being anandamide (N- arachidonoylethanolamine
or AEA) and 2-arachidonoyl-glycerol (2-AG). FAAH is
responsible for the degradation of AEA, while MAGL
degrades 2-AG (Gowran et al., 2010). The ECB sys-
tem functions to modulate locomotion, memory, feeding
behaviour, analgesia, energy balance and metabolism,
stress response, sleep and many other processes (Pacher,
2006).
AEA and 2-AG mainly bind to two types of G-protein
coupled receptors (GPCRs): CB1 and CB2 receptors
(Gowran et al., 2010). They also bind to a lesser extent
to other receptors, such as GPCR 55 (GPR55) (Ross,
2009) and GPCR 18 (GPR18) (McHugh et al., 2010).
These are orphan receptors that are involved in the as-
sembly and mobilization of microglia, and the regulation
of neuropathic pain (Gowran et al., 2010). CBs can
also bind to transient receptor potential cation chan-
nel subfamily V member 1 (TRPV1) (To´th, Blumberg
& Bocza´n, 2009), which plays a role in inflammation
and pain (Costa et al., 2010), in addition to the ab-
normal cannabidiol receptor (McHugh et al., 2010) and
the peroxisome proliferator-activated receptor (PPAR)
(O’Sullivan, 2009). The function of GPR55, GPR18
and TRVP1 highlights them as potential targets in dis-
eases involving neuropathic pain and neuroinflamma-
tion (Gowran et al., 2010). CB receptors are extens-
ively found in the body, but are mainly concentrated
in the central nervous system (CNS) and the immune
system. CB1 receptors are differentially distributed in
the CNS (Herkenham, Lynn, Johnson & Melvin, 1991),
whilst CB2 receptors are mostly found in the immune
system (Gowran et al., 2010), on cells like T-cells, B-
cells and monocytes, and in organs such as the spleen.
In the CNS, CB2 receptors are restricted to the brain-
stem (Van Sickle, 2005) and on microglia (Nu´n˜ez et al.,
2008). CB receptors can also be found to a lesser extent
in the peripheral nervous system, reproductive organs,
cardiovascular system and the gastrointestinal system
(Babayeva et al., 2016).
The ECB 2-AG is 150 times more abundant in the
brain than AEA and it binds to CB receptors much
more potently (Buczynski & Parsons, 2010). It is the
main ECB released in the midbrain in a calcium ion
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dependent fashion. ECBs regulate synaptic transmis-
sion via “retrograde signaling”; one important feature
of these ECBs is that they are synthesized on demand.
Once ECBs are synthesized on the post-synaptic mem-
brane, they travel across the synaptic cleft to bind to
CB1 receptors on the presynaptic elements, where they
cause cessation of neurotransmitter release (Gowran et
al., 2010). This is possible because, on binding to
the receptor (which is associated with a specific Golf
protein), ECBs inhibit voltage-gated calcium channels
and increase the activity of inward rectifying potassium
channels in the presynaptic cell (Le´ve´ne`s, Daniel, Sou-
brie´ & Cre´pel, 1998; Kreitzer & Regehr, 2001; Reggio,
2010). The calcium channel can be of the L-type, Q/P-
type and N-type (Melis & Pistis, 2007). In this way,
ECBs may protect against excessive excitation or in-
hibition (Lovinger, 2008). ECBs prevent the release
of GABA on binding to CB1 receptors; this process
is thus known as depolarization induced suppression of
inhibition (DSI). The same process occurs in glutam-
inergic neurons, but in this case the process is called
depolarization induced suppression of excitation (DSE)
(Alger, 2002; Heinbockel, 2005). Serotonin (5-HT),
acetylcholine and opioid peptides are other examples
of neurotransmitters that can be modulated via CBs
(Heifets & Castillo, 2009). Following activation of its
receptor, the ECB is removed from the synapse via AEA
membrane transporters (Melis & Pistis, 2007).
2 Effect of Some Cannabinoids on the
Endocannabinoid System
2.1 ∆9-tetrahydrocannabinol
∆9-THC is a partial agonist of both CB1 and CB2 re-
ceptors. The strength of the response it generates on
binding to receptors depends on the concentration of
receptors and the efficiency of their signalling. It is
also affected by continuous liberation of ECBs (Per-
twee, 2008). The chemical structure of ∆9-THC re-
sembles that of AEA, implying that it mimics the effect
of ECBs. It has been shown to enhance appetite and
cause smooth muscle relaxation (Petrocellis, Cascio &
Marzo, 2004). Smoking ∆9-THC results in the imme-
diate onset of its effects, since the drug enters the cir-
culation directly from the lungs. These effects become
apparent within minutes and are known as a “high”.
Since ∆9-THC exerts its effect on cannabinoid receptors,
which are highly concentrated in the CNS, the smoker
experiences changes in conscious perception, euphoria
and feelings of well-being. This occurs because the ECB
system is over-stimulated (Basavarajappa, 2007). When
used short term, ∆9-THC also influences the dopamin-
ergic system by stimulating dopamine release, however,
it has the opposite effect if used chronically (Bloomfield,
Ashok, Volkow & Howes, 2016).
2.2 Cannabidiol
Cannabidiol (CBD) has different effects on the CB sys-
tem as it binds to CB1 and CB2 receptors sparingly, but
it is still able to block the action of ∆9-THC indirectly.
This would theoretically diminish the effect of ∆9-THC.
However, the effect is the opposite, as CBD causes up-
regulation of CB1 receptors (Devinsky et al., 2014). Its
influence on the action of ∆9-THC gives it the ability
to control several side effects associated with ∆9-THC,
such as tachyarrhythmia and increased appetite (Russo,
2011). CBD also supplements some of ∆9-THC’s de-
sired outcomes by helping to reduce its psychotic effects,
making it more tolerable to the patient and increasing
its therapeutic window (Karniol & Carlini, 1973). CBD
has also been shown to help with psychosis by prevent-
ing ECBs from being catabolized, thus prolonging their
activity (Leweke et al., 2012). CBD can also act as an
inverse agonist of the CB2 receptor, which allows it to
prevent immune system cells from migrating (Pertwee,
2008). CBD delays the uptake of the neurotransmit-
ter adenosine, thus increasing the levels of adenosine
A1 receptor activation in the brain, which neutralizes
a portion of the effects of activation of CB1 receptors
(Devinsky et al., 2014).
2.3 ∆9-tetrahydrocannabivarin
∆9-tetrahydrocannabivarin (∆9-THCV) is another can-
nabinoid extracted from marijuana which mimics ∆9-
THC. Like ∆9-THC, it binds with equal efficacy to both
CB1 and CB2 receptors, but its effects are several times
less potent. In vitro, it is a CB2 receptor partial agonist,
while in vivo it is a CB1 receptor agonist (it is a CB1 re-
ceptor antagonist at lower concentrations). However, in
tissues that contain CB1 receptors, it blocks cannabin-
oid receptor agonists (Pertwee, 2008).
3 Parkinson’s Disease
Neurodegenerative disorders, which include PD, have
also been extensively studied in the context of finding
cannabinoid (CB)–based therapy (Gowran et al., 2010).
The neurodegeneration associated with this disease oc-
curs in dopaminergic cells of the nigrostriatal system.
The main functional component of the basal ganglia af-
fected is the substantia nigra pars compacta (SNc), loc-
ated in the midbrain. As a result, there is a lack of
dopamine in the striatum, leading to less excitation of
the direct striatonigral pathway that facilitates move-
ment, and less inhibition of the indirect pathway that
antagonizes movement. Degeneration of the SNc neur-
ons occurs over a prolonged period and can take up to
several decades (Galvan & Wichmann, 2008). The cause
of this is not well known but has been linked to both en-
vironmental factors, such as pesticides and certain anti-
psychotics, as well as genetic factors, such as mutations
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in certain genes that encode proteins, like PINK1 and
parkin (Gowran et al., 2010).
PD has both motor and non-motor symptoms. The
non-motor symptoms appear before the motor symp-
toms, with the clinical diagnosis made after there
is a significant loss of nigrostriatal dopamine (about
70%) (Bernheimer, Birkmayer, Hornykiewicz, Jellinger
& Seitelberger, 1973). Since dopamine facilitates move-
ment, PD patients exhibit hypokinesia, along with other
motor symptoms such as bradykinesia and akinesia,
muscle stiffness, and resting tremor (Thomas & Beal,
2007; Galvan & Wichmann, 2008; Rodriguez-Oroz et
al., 2009). Non-motor symptoms that may be experi-
enced include low blood pressure on pertaining an up-
right posture, depression, difficulty in defecation, anxi-
ety and sleep disorders. When the disease has pro-
gressed significantly, dementia may also occur (Velse-
boer, de Haan, Wieling, Goldstein & de Bie, 2011; Con-
nolly & Fox, 2013; Stocchi et al., 2014). At present,
the common approach towards the treatment of mo-
tor symptoms involves dopamine replacement therapy
(Goetz & Pal, 2014). This is achieved via several means,
the main one being administration of dopamine pre-
cursor levodopa (L-DOPA) (Pantcheva, Reyes, Hoover,
Kaelber & Borlongan, 2015). Other approaches are: (1)
limiting dopamine break down with catechol-O- methyl-
transferase (COMT) inhibitors, (2) stimulating dopam-
ine receptors with dopamine agonists (i.e., Sinemet),
and (3) enhancing dopamine release while preventing
reuptake of dopamine at presynaptic terminals (Lees,
2005; Goetz & Pal, 2014). Although effective, the effic-
acy of L-DOPA treatment tends to decrease when used
chronically and may also cause significant side effects.
Furthermore, L-DOPA only caters specifically to the
motor symptoms of the disease as non-motor symptoms
do not respond to this type of treatment (Pantcheva et
al., 2015).
Certain drugs, such as monoamine oxidase B (MAO-
B) inhibitors and COMT inhibitors, are effective in lim-
iting the adverse effects caused by L-DOPA. In addition
to these, dopamine agonists, apart from being used in
early stages to treat the disease, are also useful in de-
creasing the motor fluctuations associated with L-DOPA
therapy (Pahwa et al., 2006). The various difficulties as-
sociated with the forms of therapy mentioned has initi-
ated research into alternative approaches, among them,
medical marijuana. Several studies have shown that dif-
ferent phyto-CBs can be used to treat various symptoms
that accompany PD, including both motor and non-
motor symptoms (Babayeva et al., 2016), by counter-
acting oxidative stress, neuroinflammation and excito-
toxicity (Ferna´ndez-Ruiz et al., 2013).
3.1 The Endocannabinoid System and
Dopamine
The ECB system is central in regulating dopaminergic
transmission and motor functions, hence it is highly ex-
pressed in the basal ganglia (El Manira & Kyriakatos,
2010). The globus pallidus and the SNc are compon-
ents of the basal ganglia associated with locomotion and
cognition, and they express large amounts of CB1 re-
ceptors and ECBs (especially AEA) (Babayeva et al.,
2016). These CB1 receptor expressing neurons (includ-
ing GABAergic and glutamatergic cells) are found close
to, or in contact with, dopaminergic neurons. Nigrostri-
atal dopaminergic neurons do not contain CB1 receptors
(Ferna´ndez-Ruiz, Lastres-Becker, Cabranes, Gonza´lez &
Ramos, 2002). However, ECBs can exert their effect on
dopaminergic signalling indirectly (van der Stelt & Di
Marzo, 2003). Therefore, alterations in the ECB sys-
tem considerably affect the nigrostriatal dopaminergic
function. For example, activation of CB1 receptors on
GABAergic neurons results in decreased GABA release
onto dopaminergic neurons in the SNc, thus resulting in
their disinhibition (Ferna´ndez-Ruiz, 2009).
On the contrary to CB1 receptors, CB2 receptors are
found on dopaminergic neurons (M. Garc´ıa, Cinquina,
Palomo-Garo, Ra´bano & Ferna´ndez-Ruiz, 2015). This
indicates an immediate relationship between dopamin-
ergic signalling and the ECB system. Also, some ECBs
may be produced by the soma and dendrites of the
dopaminergic cells themselves, which would act on the
pre-synaptic cell as described previously, hence neuro-
transmitter release onto dopaminergic cells would be re-
duced (Riegel, 2004). The major factor promoting ECB
release from dopaminergic cells is electrical stimulation
of the aforementioned dopaminergic cell. This eventu-
ally causes the release of calcium ions from intracellu-
lar stores, thus promoting ECB release. Suppression
of sn1-specific diacylglycerol lipase, which is responsible
for the synthesis of 2-AG, leads to the cessation of syn-
aptic modulation. This implies that dopaminergic cells
synthesize 2-AG rather than AEA (Melis, 2004).
There are other connections between the dopaminer-
gic system and ECBs, one of them being that the re-
ceptor TRPV1, which can bind to AEA, can be found
on dopaminergic neurons (Mezey et al., 2000). The CB1
receptor is capable of forming heteromeric dimers with
the dopamine receptors D1 and D2, which are both G
protein-coupled. Additionally, CB1 receptors and D2 re-
ceptors make use of a common pool of G-proteins, which
points to overlap in intracellular signalling (Ferre´, Gold-
berg, Lluis & Franco, 2009). It has also been shown
that D2 receptors in the striatum control the produc-
tion of AEA. These associations prove that there is a
link between the motor activity induced by dopamine
and the ECB system, with the ECB system controlling
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it via a negative feedback response (Giuffrida et al.,
1999). The link between the ECB system and dopam-
inergic, GABAergic and glutaminergic signalling makes
it an appropriate focal point in the search for drugs to
treat PD.
Figure 1: A schematic drawing depicting the way cannabinoids interact with the dopaminergic system in the basal ganglia. Taken
from Stampanoni Bassi, Sancesario, Morace, Centonze and Iezzi (2017).
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4 Alterations in the Endocannabinoid
System in Parkinson’s Disease
Various studies have shown that the dopamine depletion
occurring in PD leads to changes in the ECB system and
a disequilibrium between the direct and indirect path-
ways of the basal ganglia that regulate movement (V.
Pisani et al., 2010).
4.1 Changes in Anandamide Levels
Neurotoxin 6-hydroxydopamine (6-OHDA) is known to
mimic the lack of dopamine experienced in PD when
infused into the SNc or the striatum of rodent brains; it
also induced higher AEA levels (Giuffrida et al., 2004).
Similar results were obtained in a group of PD sufferers
(with varying degrees of severity), showing double AEA
levels than that of the concentration found in control
patients. It was also found that AEA levels did not
vary with the severity of the disease (A. Pisani et al.,
2005).
The rise in AEA might be a compensatory mechan-
ism to make up for the loss of dopamine, as studies have
shown that AEA reduces the over-activity of glutama-
tergic cortico-striatal pathways in rodents injected with
6-OHDA (Giuffrida et al., 2004).
4.2 Changes in CB1 Receptors
CB1 receptors are found on corticostriatal glutamatergic
neurons and on GABAergic neurons innervating the me-
dial globus pallidus, lateral globus pallidus and the SNc,
as well as in excitatory projections from the subthalamic
nucleus to the medial globus pallidus and the SNc (Ben-
arroch, 2007). They are also located in striatum par-
valbumin immune-reactive interneurons, cholinergic in-
terneurons, and neurons that contain nitric oxide syn-
thase (Fusco et al., 2004). In PD patients, basal ganglia
nuclei exhibit high amounts of mRNA encoding CB1 re-
ceptors. This occurs in the intermediate and late stages
of the disease when motor symptoms start appearing.
In contrast, in the early stages of the disease, CB1 re-
ceptors are down-regulated (Gowran et al., 2010). Due
to the lack of CB1 receptors, there is a lack of inhibi-
tion of glutamate release, which can cause excitotoxicity
(van der Stelt et al., 2002). These changes can be ap-
plied to medication for PD, which will be discussed in
the next paragraphs.
5 Different Approaches to Reversing
Endocannabinoid Changes in PD
5.1 CB1 Receptor Agonists
Cannabinoid agonists promote hypokinesia, while can-
nabinoid antagonists endorse hyperkinesia. Hypokin-
etic effects are mediated via CB1 receptor activation
(Bisogno et al., 1999). In the case of CB agonists, they
can be in the form of synthetic cannabinoids, ECBs, or
phyto-CB (de Lago, de Miguel, Lastres-Becker, Ramos
& Ferna´ndez-Ruiz, 2004). Studies have shown that the
synthetic cannabinoid HU-210 decreases LID and causes
a decline in glutaminergic signalling on activation of
CB1 receptors (Gilgun-Sherki, Melamed, Mechoulam &
Offen, 2003). When Park-2 knockout (KO) mice (which
depict a model of early-stage PD) were treated with
∆9-THC, they were reported to have high tyrosine hy-
droxylase levels, which is a critical enzyme in the syn-
thesis of dopamine. They also experienced hypokin-
esia. However, it was of much less significance than
that experienced by control mice (Gonza´lez et al., 2005).
This is consistent with the fact that CB1 receptors are
down-regulated in the early stages of the disease. Treat-
ment with ∆9-THC and two other synthetic cannabin-
oids (WIN 55,212-2 and CP 55,940) has been shown
to increase dopamine levels (Romero et al., 2002). Des-
pite the undesired hypokinetic effects of cannabinoid ag-
onists (except in the case of alleviating dyskinesia), it
has been observed that they have beneficial properties
when it comes to the neurodegeneration that occurs in
PD. A drug named Sativex (which contains both ∆9-
THC and CBD) may be used in treatment of PD, since
the CBs in it have been found to act as antioxidants
and protect nigrostriatal dopaminergic neurons from 6-
OHDA-lesion (Lastres-Becker, Molina-Holgado, Ramos,
Mechoulam & Ferna´ndez-Ruiz, 2005). This neuropro-
tective property suggests that cannabinoid agonists not
only help treat symptoms, but also prevent the disease
from progressing further.
5.2 CB1 Receptor Antagonists
In the late stages of the disease, CB1 receptor antagon-
ists can be used to hinder the effects of high CB1 re-
ceptor density. This was investigated in a study where
rodents were injected with 6-OHDA to mimic the hy-
pokinesia experienced in PD. CB1 receptors were found
to be up-regulated in these rats. The specific CB1 re-
ceptor antagonist rimonabant was found to be effective
against motor inhibition. However, this was only ef-
fective when the drug was administered at small doses
and was unrelated to dopamine, GABA and glutam-
ate signalling in the striatum (Gonza´lez et al., 2006).
In another study, PD-lesioned animals were admin-
istered varying concentrations of rimonabant and ex-
perienced an increase in glutamatergic function in the
striatum, but this occurred only at the highest dose
administered (of 1 mg/kg) (Garc´ıa-Arencibia, Ferraro,
Tanganelli & Ferna´ndez-Ruiz, 2008). The combined
use of rimonabant with L-DOPA diminishes the dys-
kinesia associated with PD (Segovia, Mora, Crossman
& Brotchie, 2003). Rimonabant has also been shown to
reverse the effects of ∆9-THC (Di Marzo et al., 2001),
and prevent the increase in dopamine that is caused by
∆9-THC (Tanda, 1997). Despite the success in other
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animal species, rimonabant is not effective in primate
species (Meschler, Howlett & Madras, 2001). Other
CB1 receptor antagonists, including THCV, are effect-
ive against alterations in glutaminergic transmission and
prevention of hypokinesia in rodents, thus alleviating
symptoms and slowing disease progression (C. Garc´ıa
et al., 2011).
5.3 Modifying Endocannabinoid Levels
Since FAAH is the primary enzyme responsible for
the degradation of AEA, FAAH inhibitors can be
used to manipulate the levels of endogenous cannabin-
oids. Interestingly, the enzyme is already present at
lower than normal concentrations in patients with PD.
The FAAH inhibitor [3-(3-carbamoylphenyl)phenyl] N-
cyclohexyl carbamate (URB597) has been proven to in-
crease AEA levels, which in turn causes dopamine levels
to rise (Solinas, Justinova, Golberg & Tanda, 2006).
URB587 is responsible for reducing side effects associ-
ated with L-DOPA treatment, such as impulse control
disorder and dopamine dysregulation syndrome, while
still reaping the anti-Parkinsonian benefits of L-DOPA
(Johnston et al., 2010).
5.4 CB2 Receptor Agonists
CB2 receptors have been shown to play a role in the
neurological inflammation that occurs in PD. The SNc
microglial cells of patients with PD express higher than
normal level of CB2 receptors (Go´mez-Ga´lvez, Palomo-
Garo, Ferna´ndez-Ruiz & Garc´ıa, 2016). Neuroinflam-
mation can be induced in rats by striatal injection of
lipopolysaccharide (LPS) to mimic inflammation which
occurs in PD. It was shown that CB2 receptor KO mice
experienced an increased loss of SNc dopaminergic cells.
This suggests that CB2 receptors have a neuroprotect-
ive effect. CB2 receptor KO mice also showed a higher
rise in CD68 immunostaining (which corresponds to ac-
tivated microglia and macrophages) than wild type an-
imals. When the inflamed brain was treated with HU-
308 (a CB2 agonist), the neuroinflammation induced by
LPS was counteracted and there was a fall in CD68 im-
munostaining. A selective CB2 receptor agonist HU-308
has also been shown to counteract the increase in pro-
inflammatory mediators caused by LPS (Go´mez-Ga´lvez
et al., 2016).
5.5 Cannabinoids and the Motor Symptoms of
PD
As far as the motor symptoms of PD are concerned,
studies have shown that cannabinoids are beneficial in
preventing dyskinesia induced via dopamine replace-
ment therapy (Sieradzan et al., 2001), as well as helping
with PD symptoms such as resting tremors, rigidity, bra-
dykinesia and postural instability (Consroe, Sandyk &
Snider, 1986; Venderova´, Ruzˇicˇka, Vorˇ´ıˇsek & Viˇsnˇovsky´,
2004).
5.6 Effect of Cannabinoids on Parkinsonian
Motor Symptoms
in a survey study, Venderova´ and colleagues (2004)
found that 45.9% of a group of PD patients found can-
nabis helpful overall, with regards to the alleviation of
Parkinsonian motor symptoms. The degree of improve-
ment varied from mild to significant. Moreover, 30.6%
experienced fewer resting tremors, 44.7% experienced an
improvement with bradykinesia, and 37.7% experienced
less muscular rigidity. Almost all of these patients ad-
ministered cannabis orally, most often with meals and
with a frequency of once every single day. Besides from
one patient who had only ingested cannabis once, before
the day of testing, all patients had been taking cannabis
for several months. Only a small percentage of parti-
cipants (4.7%) felt that cannabis made their condition
worse. On average, it took approximately two months
from first ingestion for patients to experience any be-
nefits. PD patients on cannabis were tested for 11-nor-
9-THCOOH (which is one of the main metabolites of
∆9-THC). It was found that those with a high concen-
tration of this metabolite in their urine (> 50 ng/ml)
experienced improvements in bradykinesia and rigidity,
while those with a low concentration of the metabol-
ite in their urine (< 50 ng/ml) experienced no improve-
ments. Interestingly, the patient who had only taken
cannabis on one occasion had very high levels of 11-nor-
9-THCOOH, but did not experience any improvements.
This suggests that chronic use is essential in order for
cannabis to work (Venderova´ et al., 2004).
In another study, several PD patients were assessed
before and after smoking marijuana, using the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS). Their
scores improved significantly after smoking cannabis,
both in patients with response fluctuations and in pa-
tients who lacked response fluctuations (Lotan, Treves,
Roditi & Djaldetti, 2014).
Out of the four main motor symptoms of PD (bra-
dykinesia, postural instability, resting tremor, rigidity),
postural instability was the only one that did not im-
prove with smoking marijuana. The effect of smoking
marijuana lasted around 3 hours (Lotan et al., 2014).
5.7 Effect on L-DOPA Induced Dyskinesia
There are different hypotheses with regards to the cause
of dyskinesia after dopamine replacement therapy. It
has been suggested that it occurs because the lateral
globus pallidus (GPl) is overexcited (Sieradzan et al.,
2001). Interestingly, CB1 receptors are very numer-
ous on the membrane of the pre-synaptic GABAer-
gic neurons of the striatopallidal pathway (Sieradzan
et al., 2001). Activation of these CB1 receptors re-
duces GABA release, thus increasing GPI GABAergic
signalling and reversing dyskinesia. PD patients with
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dyskinesia were assessed using the Rush Dyskinesia Dis-
ability Scale following intake of the CB1 receptor agonist
nabilone. These patients’ scores were greatly improved
compared to those who had taken a placebo (Sieradzan
et al., 2001), and this effect is dependent on CB1 recept-
ors (More & Choi, 2015). Nabilone is also effective as
an antidyskinetic in 1-methyl-4-phenyl-1,2,5,6 tetrahy-
dropyridine (MPTP)-lesioned monkeys treated with L-
DOPA. Furthemore, the pharmacological effects of L-
DOPA were enhanced by 76% when given in conjunction
with nabilone (Fox, Henry, Hill, Crossman & Brotchie,
2002). In one particular study, 14.1% of a group of PD
sufferers experienced improvement of LID after intake
of cannabis. It was noted that patients taking cannabis
regularly (not less than once per day) were more likely to
experience beneficial effects with regards to dyskinesia
(Venderova´ et al., 2004).
5.8 Contraindications of Cannabis Use in
Treating Motor Symptoms
Many studies have shown marijuana to be ineffective in
treating motor symptoms. For instance, Carroll and col-
leagues showed that ingested marijuana was ineffective
in treating both Parkinsonian symptoms and LID (Car-
roll et al., 2004). The drug Cannador (which contains
unequal parts CBD and ∆9-THC) was proven to be in-
effective in the treatment of LID and other motor symp-
toms (Carroll et al., 2004). Cannabis did not affect PD
induced tremors (Stampanoni Bassi et al., 2017). Stand-
ardized methods, including the UPDRS score, were used
to assess motor fluctuations and LID after administra-
tion of the CB1 receptor antagonist rimonabant, which
was shown to be ineffective against both (Mesnage et al.,
2004). A review by the American Academy of Neurology
concluded that cannabis is ineffective in treating dyskin-
esia (Koppel et al., 2014). The inconsistencies between
research findings imply that the use of cannabis to treat
the motor symptoms of PD should be investigated more
thoroughly.
6 Cannabinoids and the Non-Motor
Manifestations of PD
6.1 Effect on Sleep
It has been established that PD sufferers experi-
ence problems with sleep (Murillo-Rodriguez, Pastrana-
Trejo, Salas-Criso´stomo & De-la-Cruz, 2017). This can
be attributed to 2 factors, dopamine-related therapy (es-
pecially dopamine agonists), as well as the direct ef-
fects of the disease, which result in alterations in the
sleep-wake cycle. Patients most commonly complain of
fragmented sleep, disproportionate tiredness and para-
somnia (Factor, McAlarney, Sanchez-Ramos & Weiner,
1990). Patients with PD experience a disturbance in
rapid eye movement (REM) sleep, with lack of reduc-
tion of normal muscle atonia, thus they physically act
out their dreams. This disorder is known as REM sleep
behaviour disorder (RBD) (Lin & Chen, 2018).
Moreover, PD patients are prone to experience night-
mares, resulting in them flailing their limbs and shouting
in their sleep (Murillo-Rodriguez et al., 2017). CBD is
the main cannabinoid associated with curing sleep dis-
orders in PD. It helps treat behaviours related to RBD
without causing any undesired effects. In four unrelated
cases of PD with RBD, CBD improved RBD-related be-
haviours, and these symptoms returned on cessation of
treatment (Chagas et al., 2014). These findings sug-
gest that cannabis can improve the quality of life of PD
patients by ameliorating their sleep.
6.2 Effect on Depression
Depression is present in 40% of PD patients. How-
ever, its cause is unclear (Barrero et al., 2005; Marsh,
2013). It may be a result of neurodegeneration in cer-
tain parts of the brain, or it may occur secondary to
the symptoms of the disease as they impair the quality
of life (Barrero et al., 2005). While there is a correla-
tion between the severity of symptoms and occurrence
of depression, depression is more common in PD than
any other neurological disorder, which implies that the
neurological changes that occur in this disease play a
role in the occurrence of depression (Tandberg, 1996).
Alterations in neurotransmitter signalling are associated
with depression. For example, dopamine depletion plays
a role in the development of depression, since it leads to
anhedonia, lack of motivation and apathy (Cummings,
1992). Changes in CB1 receptor density may play a
role in the development of depression as they interact
with the monoamine systems. By activating CB1 re-
ceptors, ∆9-THC inhibits the synaptic release of dopam-
ine, serotonin, GABA and norepinephrine, and its influ-
ence on dopaminergic and serotonergic function could
be the cause of depression in cannabis users (Musty &
Kaback, 1995).
Moreover, the limbic system of rats shows high mRNA
levels of CB1 receptor genes, which is implicative of the
association of CB1 receptors with emotions (Matsuda,
Bonner & Lolait, 1993). There is a correlation between
the occurrence of depression and expansion (of less than
sixteen repeats) on one of the alleles of the gene for CB1.
There is a highly polymorphic triplet sequence (AAT)
on the CNR1 gene that is repeated varying amounts of
times in different patients. If the gene is longer (i.e. the
number of AAT repeats is higher), the likelihood of de-
pression in PD patients decreases because it is less likely
that the gene will be transcribed (Barrero et al., 2005).
Several studies have shown that moderate marijuana
use has anti-depressive effects. For example, activat-
ing CB1 receptors via ∆9-THC, increased serotonergic
function and had anti-depressive effects (Bambico, Hat-
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tan, Garant & Gobbi, 2012) in rats. The anti-depressive
effect of ∆9-THC is CB1 receptor-mediated, as it ceases
when the CB1 receptor antagonist rimonabant is admin-
istered (Navarro et al., 1997). Preventing the degrad-
ation of AEA also results in anti-depressive effects and
enhances the activity of serotonin and norepinephrine
in the midbrain (Gobbi et al., 2005). A study on the
effects of cannabis on PD symptoms showed that 91.5%
of subjects described their emotional state as depressed
before cannabis treatment, with most of these patients
reporting an improvement in mood following cannabis
use (Balash et al., 2017).
6.3 Effect on Pain
The ECB system is expressed in various areas of the
brain and spinal cord that modulate pain (Calignano,
Rana, Giuffrida & Piomelli, 1998). AEA interacts with
CB1 receptors in these areas to modulate pain pathways
(Calignano et al., 1998). Pain is very commonly exper-
ienced in PD patients (Dworkin et al., 2003). Many an-
algesics have been used over the years, including gabap-
entin and opioids, but these have been associated with
many adverse effects (Dworkin et al., 2003). Pain in
PD has been linked to the presence of a single nuc-
leotide polymorphism (SNP) in the gene encoding the
FAAH enzyme (Greenbaum et al., 2012). Patients with
PD experienced pain relief 30 minutes after smoking
marijuana, which may be attributed to the feelings of
well-being induced by the drug, as well as to its psy-
choactive effects (Lotan et al., 2014). In one study, 114
patients with PD (or Parkinson-plus syndromes) who
experienced pain were treated with various analgesics.
It was concluded that non-steroidal anti-inflammatory
drugs (NSAIDs) were the most effective in treating pain
(78% effective), and these were followed closely by med-
ical marijuana (77% effective) (Yust-Katz, Hershkovitz,
Gurevich & Djaldetti, 2017).
6.4 Neuroprotective Effect
Phyto-CBs prevented damage to neurons in models of
PD due to their antioxidative properties and their ability
to alter glial cell signalling (Lastres-Becker et al., 2005).
CBD is both an antioxidant and an anti-inflammatory
agent, which points to its ability to offer neuroprotec-
tion in PD patients. CBD can cross the blood-brain
barrier and exert its effects on the brain. It was found
that high concentrations of CBD are not toxic to PC12
treated cells, thus demonstrating its low toxicity, in fact
CBD improved the viability of MPP+ treated PC12
cells, its effect being most successful at low doses (San-
tos et al., 2015). CBD prevents the death of dopamin-
ergic neurons, thus aiding dopaminergic function in rat
models of PD (Lastres-Becker et al., 2005; C. Garc´ıa
et al., 2011). CBD attenuates reactive oxygen species
and prevents the increase in expression of NADPH ox-
idase 1 and 4 (NOX1 and NOX4) (Pan et al., 2008).
The superoxide produced by NOX enzymes is involved
in the demise of dopaminergic cells in PD animal mod-
els (Hernandes, Cafe´-Mendes & Britto, 2013). CBD de-
creases the formation of inducible nitric oxide synthase
(iNOS) (Pan et al., 2008) and enhances the production
of Cu2+, Zn-superoxide dismutase mRNA, which when
transcribed, prevents the formation of reactive oxygen
species (Garc´ıa-Arencibia et al., 2007).
Cannabinoids can act as anti-inflammatory agents by
preventing activation of microglia (which are found at
higher levels in the SNc of patients with PD) and inhib-
iting the release of toxic cytokines (Sayd et al., 2014).
Therefore, cannabinoids indirectly prevent dopaminer-
gic cell death by counteracting neuroinflammation, one
of the factors that contributes to their death (Clark
& Kadodek, 2016). Cannabinoids also protect against
neuroinflammation via reperfusion of the site of injury
and by reversing vasoconstriction (Sagredo et al., 2007).
CB2 receptor agonists (including cannabinoids) cause
up-regulation of these receptors in microglia of the SNc,
and also offer neuroprotection to dopaminergic neurons
by shielding them from the neuroinflammation caused
by the same activated microglia (C. Garc´ıa et al., 2011).
Brain slices from Wistar rats were oxygen and glucose
deprived, after which they were treated with the can-
nabinoid CB1/CB2 receptor agonist WIN55212. This
drug prevented cell damage, production of nitric oxide
and release of glutamate, among other neurotoxic ef-
fects (Ferna´ndez-Lo´pez et al., 2006). By activating CB1
receptors, ∆9-THC also acts as an anti-inflammatory
agent (Fishbein-Kaminietsky, Gafni & Sarne, 2014).
CBD has been combined with ∆9-THC in various drugs,
one of which is Sativex, and together, they have been
proven to have neuroprotective effects (Iuvone, Es-
posito, De Filippis, Scuderi & Steardo, 2009). ∆9-THC
can augment the survival of dopaminergic cells and en-
hance the activity of PPARγ receptors (Zeissler, Hane-
mann, Zajicek & Carroll, 2012). Apart from having
neuroprotective properties of its own, CBD helps reduce
the side effects associated with ∆9-THC administration.
In such drugs, CBD and THC interact with both CB1
and CB2 receptors (Sagredo et al., 2011).
Additionally, ∆9-THCV plays a role in neuroprotec-
tion (C. Garc´ıa et al., 2011). In the long term, it coun-
teracts the loss of dopaminergic cells in the SNc, which
occurs as a result of 6-OHDA treatment. It also prevents
the activation of microglia. It is likely that both of these
effects are caused by ∆(9)-THCV’s antioxidant proper-
ties, rather than its action on CB2 receptors, since they
were also observed on treatment with CBD. To further
support this hypothesis, when CB2 receptor KO mice
were treated with 6-OHDA, their loss of dopaminergic
cells was of the same degree as wild type mice, imply-
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Table 1: An overview of the action of different cannabinoids on motor and non-motor PD symptoms.
Effect of cannabinoids on motor impairments
∆9-THC (> 50 ng/ml of
its metabolite 11-nor-∆-9-
THCOOH detected in ur-
ine)
Humans Improvement of bradykin-
esia and rigidity
Venderova´, Ruzˇicˇka,
Vorˇ´ıˇsek and Viˇsnˇovsky´
(2004)
Smoked cannabis (inhaled
amount: 0.5 g)
Humans Improvement of tremor,
rigidity, bradykinesia.
Little effect on posture
Lotan, Treves, Roditi and
Djaldetti (2014)
Nabilone (dose not spe-
cified)
Humans and primate
models
L-DOPA induced dyskin-
esia
More and Choi (2015)
Effect of cannabinoids on sleep
CBD (75 mg/day and
300 mg/day were both
effective)
Humans REM sleep behaviour dis-
order related behaviour
Chagas et al. (2014)
Effect of cannabinoids on depression
∆9-THC (repeated ad-
ministration of 1 mg/kg)
male adult Sprague–
Dawley rats
Improved serotonergic
function
Bambico, Hattan, Garant
and Gobbi (2012)
Smoked cannabis
(0.9± 0.5 g/day)
Humans Improved mood Balash et al. (2017)
Effect of cannabinoids on pain
Cannabis (dose not spe-
cified)
Humans Pain relief Yust-Katz, Hershkovitz,
Gurevich and Djaldetti
(2017)
Smoked cannabis (inhaled
amount: 0.5 g)
Humans Pain relief Lotan, Treves, Roditi and
Djaldetti (2014)
Neuroprotective effect of cannabis
CBD (1 µm dose was most
effective)
MPP+ treated PC12 cells
from rats
Antioxidant and anti-
inflammatory
Santos et al. (2015)
∆(9)-THCV (2 mg/kg−1
for 14 days)
6-hydroxydopamine-
lesioned animals
Anti-oxidant C. Garc´ıa et al. (2011)
WIN55212 (50 µm) Glucose and oxygen de-
prived brain slices from
Wistar rats
Prevents cell damage,
production of nitric oxide
and release of glutamate
Ferna´ndez-Lo´pez et al.
(2006)
ing that the presence of CB2 receptors did not affect
cell loss (C. Garc´ıa et al., 2011). However, a conflict-
ing study showed that CB2 receptors do play a role
in neuroinflammation (Go´mez-Ga´lvez et al., 2016). It
was observed in cells of the SNc and striatum that had
been treated with lipopolysaccharide (LPS), a neuro-
toxin used to mimic neuroinflammation and PD in an-
imals, these receptors were up-regulated. The amount of
activated microglia was also significantly higher in CB2
receptor deficient cells when compared to the wild type.
Furthermore, when compared to the wild type animals,
the loss of dopaminergic cells was more rapid, and oc-
curred to a greater extent, in cells lacking CB2 receptors
(Go´mez-Ga´lvez et al., 2016). An overview of the effects
of cannabinoids on the motor and non-motor symptoms
of PD can be found in Table 1.
7 Conclusion
Medical marijuana has been suggested to have some po-
tential benefits as a treatment for PD. From the liter-
ature reviewed here, CBs may be more effective against
non-motor symptoms compared to motor symptoms, al-
though meliorates LID. Marijuana has already been leg-
alized in Israel for therapy of pain and tremor in people
suffering from PD (Yust-Katz et al., 2017), and it is
effective in treating comorbid sleep problems and de-
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pression. It may act as a disease-modifying treatment
by blocking/delaying disease progression due to oxidat-
ive stress and neuroinflammation, an effect that seems
to be independent from CB receptors. Among the CBs,
the most promising in this regard seems to be CBD.
Although there are contradictory studies which today
do not support the therapeutic use of marijuana for dif-
ferent disorders such as PD, medicinal marijuana has
been legalized in various areas of the world, including
Malta. This step forward has been largely driven by
the media, politics and the public, signifying the need
for more preclinical/clinical research, including carefully
planned clinical trial studies regarding the therapeutic
effects of cannabis, in order to enable medical profes-
sionals to provide new effective cures for their patients.
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